GeneSys Bio
GeneSys Bio is a biomedical startup dedicated to providing rapid, sensitive, and specific pathogen detection technologies. With a mission to make advanced molecular diagnostics accessible everywhere, the company leverages innovative genetic technology and a sample-to-result platform to serve clinicians and patients. Their solutions aim to deliver results in less than an hour, with high accuracy, ease of use, portability, and economic efficiency, focusing initially on urinary tract infections and expanding to various infectious challenges in humans, animals, and the environment.
Industries
Nr. of Employees
small (1-50)
GeneSys Bio
Products
Sample-to-result PCR-based diagnostic platform for rapid pathogen detection
Integrated, portable platform that automates PCR-based molecular workflows to deliver rapid, sensitive and specific pathogen detection results at point of need.
Sample-to-result PCR-based diagnostic platform for rapid pathogen detection
Integrated, portable platform that automates PCR-based molecular workflows to deliver rapid, sensitive and specific pathogen detection results at point of need.
Services
Collaborative development of molecular assays and integrated diagnostic devices intended for rapid, on-site pathogen detection and monitoring.
Prototype device construction and early-stage technical validation to demonstrate feasibility and support further development or investment.
Collaborative development of molecular assays and integrated diagnostic devices intended for rapid, on-site pathogen detection and monitoring.
Prototype device construction and early-stage technical validation to demonstrate feasibility and support further development or investment.
Expertise Areas
- Molecular diagnostics development
- Point-of-care device engineering
- Assay development for infectious diseases
- Antimicrobial resistance diagnostics
Key Technologies
- Polymerase chain reaction (PCR)-based diagnostics
- Sample-to-result automation
- Point-of-care portable diagnostic hardware
- AI-driven diagnostic optimization
News & Updates
GeneSys Bio selected to participate in the Berkeley SkyDeck accelerator program in November 2024.
GeneSys Bio selected from over 120 applicants to participate in the Startup Program during Rome Startup Week 2024 in September 2024.
GeneSys Bio selected to present in front of more than 100 VC investors with a combined AUM of over $10 billion in September 2024.
GeneSys Bio selected among the most innovative approaches in Europe for diagnosing Sexually Transmitted Diseases in July 2024.
GeneSys Bio wins the maximum grant available through Lazio Innova's Pre-Seed Plus call in June 2024.
GeneSys Bio selected to present at the World Startup Fest in June 2024.
GeneSys Bio selected to participate in the Berkeley SkyDeck accelerator program in November 2024.
GeneSys Bio selected from over 120 applicants to participate in the Startup Program during Rome Startup Week 2024 in September 2024.
GeneSys Bio selected to present in front of more than 100 VC investors with a combined AUM of over $10 billion in September 2024.
GeneSys Bio selected among the most innovative approaches in Europe for diagnosing Sexually Transmitted Diseases in July 2024.
GeneSys Bio wins the maximum grant available through Lazio Innova's Pre-Seed Plus call in June 2024.
GeneSys Bio selected to present at the World Startup Fest in June 2024.